Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135614 | 1.00 | MAP2K1 (0.59) | MAP2K1MAP2K2IDO1AURKAPRKCB | |
| SCHEMBL31376766 | 0.90 | MAP2K1 (0.56) | MAP2K1MAP2K2IDO1AURKAPRKCB | |
| SCHEMBL24196106 | 0.88 | MAP2K1 (0.48) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL31135631 | 0.87 | MAP2K1 (0.50) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL23850846 | 0.87 | MAP2K1 (0.50) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL24195682 | 0.86 | DHODH (0.42) | MAP2K1MAP2K2DHODH | |
| SCHEMBL23851097 | 0.83 | MAP2K1 (0.62) | MAP2K1MAP2K2IDO1DHODH | |
| SCHEMBL31135615 | 0.83 | MAP2K1 (0.62) | MAP2K1MAP2K2IDO1DHODH | |
| SCHEMBL24195910 | 0.82 | MAP2K1 (0.65) | MAP2K1MAP2K2 | |
| SCHEMBL24195795 | 0.82 | MAP2K1 (0.65) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883552-B1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-3883554-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883552-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883553-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885IDO1 623/4885 |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NCOA3, TYR, CYP3A43 | MAP2K1 2772/4885MAP2K2 2465/4885IDO1 630/4885 |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CUTA, BRAF | MAP2K1 469/4885MAP2K2 291/4885IDO1 341/4885 |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | TYR, CUTA, BRAF | MAP2K1 469/4885MAP2K2 291/4885IDO1 341/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | MAP2K1 3307/4885MAP2K2 3471/4885IDO1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.